 MediciNov Inc NASDAQ: MNOV sees a trading volume of 18.5 million shares after Zacks Small Cap Research increased the stock price target to 28 from 26.5 earlier. The research notes positive results from a Phase 2 trial of MN-166 ibudilast in alcohol use disorder AUD published in Translational Psychiatry. 